ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-836-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.61 billion
Profitability
Miscellaneous
Employees7,240
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
ResMed (NYSE:RMD) Frequently Asked Questions
What is ResMed's stock symbol?
ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."
How often does ResMed pay dividends? What is the dividend yield for ResMed?
ResMed declared a quarterly dividend on Thursday, July 25th. Stockholders of record on Thursday, August 15th will be given a dividend of $0.39 per share on Thursday, September 19th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Wednesday, August 14th. This is a positive change from ResMed's previous quarterly dividend of $0.37. View ResMed's Dividend History.
How were ResMed's earnings last quarter?
ResMed Inc. (NYSE:RMD) posted its quarterly earnings data on Thursday, July, 25th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.92 by $0.03. The medical equipment provider earned $705 million during the quarter, compared to analyst estimates of $701.56 million. ResMed had a net margin of 15.52% and a return on equity of 26.49%. ResMed's revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.95 EPS. View ResMed's Earnings History.
When is ResMed's next earnings date?
What price target have analysts set for RMD?
6 Wall Street analysts have issued 12-month price objectives for ResMed's shares. Their predictions range from $95.00 to $140.00. On average, they anticipate ResMed's stock price to reach $118.3333 in the next twelve months. This suggests that the stock has a possible downside of 11.4%. View Analyst Price Targets for ResMed.
What is the consensus analysts' recommendation for ResMed?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ResMed.
Has ResMed been receiving favorable news coverage?
Headlines about RMD stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ResMed earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for ResMed.
Are investors shorting ResMed?
ResMed saw a decline in short interest during the month of July. As of July 15th, there was short interest totalling 2,300,500 shares, a decline of 6.5% from the June 15th total of 2,461,300 shares. Based on an average daily volume of 552,000 shares, the days-to-cover ratio is presently 4.2 days. Approximately 1.6% of the shares of the stock are sold short. View ResMed's Current Options Chain.
Who are some of ResMed's key competitors?
Some companies that are related to ResMed include Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), Teleflex (TFX), DexCom (DXCM), Novocure (NVCR), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED) and Cantel Medical (CMD).
What other stocks do shareholders of ResMed own?
Who are ResMed's key executives?
ResMed's management team includes the folowing people:
- Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
- Mr. Robert A. Douglas, Pres & COO (Age 59)
- Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
- Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
- Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)
Who are ResMed's major shareholders?
ResMed's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.67%), BlackRock Inc. (8.15%), BlackRock Inc. (8.15%), WCM Investment Management LLC (5.03%), Baillie Gifford & Co. (3.36%) and Northern Trust Corp (1.39%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Institutional Ownership Trends for ResMed.
Which institutional investors are selling ResMed stock?
RMD stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, BlackRock Inc., BlackRock Inc., AQR Capital Management LLC, Bank of America Corp DE, Westpac Banking Corp, Janus Henderson Group PLC and Janus Henderson Group PLC. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed.
Which institutional investors are buying ResMed stock?
RMD stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, Amundi Pioneer Asset Management Inc., Vanguard Group Inc., WCM Investment Management LLC, Jacobs Levy Equity Management Inc., Ontario Teachers Pension Plan Board and UBS Asset Management Americas Inc.. View Insider Buying and Selling for ResMed.
How do I buy shares of ResMed?
Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ResMed's stock price today?
One share of RMD stock can currently be purchased for approximately $133.52.
How big of a company is ResMed?
ResMed has a market capitalization of $19.18 billion and generates $2.61 billion in revenue each year. The medical equipment provider earns $404.59 million in net income (profit) each year or $3.64 on an earnings per share basis. ResMed employs 7,240 workers across the globe.View Additional Information About ResMed.
What is ResMed's official website?
How can I contact ResMed?
ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]
MarketBeat Community Rating for ResMed (NYSE RMD)
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
